Detemir: Role in Type 1 Diabetes

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart). It is hypothesized that there is no difference in the patterns of blood sugars when detemir is given in the same syringe or in separate syringes with rapid acting insulin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baylor College of Medicine; Montefiore Medical Center
• Treatments: Insulin; Insulin Detemir; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Subjects with antibody positive Type 1 Diabetes Mellitus (T1DM)

• On insulin glargine for at least 3 months

• Age 10-25 years

• Not on medications that may affect glucose concentrations

• Hemoglobin A1C (HbA1C) of less than 9 %

• Body Mass Index (BMI) less than 95th % and more than 10th%

• Supportive family

Exclusion Criteria:

• Subjects with undetermined diabetes or Type 2 Diabetes Mellitus (T2DM)

• Unable to adhere to insulin regimen

• Positive urine pregnancy test